中文
|
English
About
Academics
Research
Organization
Join Us!
Dean's message
Our Leadership
Our History
The School Board
School Organization
Undergraduate Programs
Master Programs
Doctoral Programs
Postdoctoral Training
Continuing Education
Research overview
Research Areas
Recent Achievements
Research platforms
Facilities
Exchange & Collaboration
Departments
Centers&Platforms
Facilities
Join Us!
导航
Open Menu
Home
About
Academics
Research
Organization
Join Us!
Your Position:
homepage
Research
Recent Achievements
Research
>>
Research overview
>>
Research Areas
>>
Recent Achievements
>>
Research platforms
>>
Facilities
>>
Exchange & Collaboration
Recent Achievements
Recent advance in the discovery of novel mu opioid receptor (μOR) agonists by Wei Fu Group and Jinggen Liu Group (SIMM)
2021/09/03
Wei Fu Group (School of Pharmacy, Fudan University) and Jinggen Liu Group (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) has made progress in the study of novel selective μOR agonists as well as a structural basis for development of potential analgesic candidates. The discovery...
Read More
Recent advance in the discovery of novel kappa opioid receptor (κOR) agonists by Liming Shao Group and Jinggen Liu Group (SIMM)
2021/08/30
Liming Shao Group (School of Pharmacy, Fudan University) and Jinggen Liu Group (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) has made progress in the study of novel κOR agonists and identification of compound SLL-1206 provides significant insights to the dissociation of analge...
Read More
Professor Renxiao Wang's group has made progress in the research of selective Mcl-1 inhibitors
2021/07/20
Apoptosis is an essential process for eliminating aging or abnormal cells in the living system. Dysregulation of apoptosis is critical for various malignant tumor diseases and drug resistance in anti-tumor therapies. Bcl-2 family proteins are key regulators of the mitochondrial apoptotic pathway. St...
Read More
Assoc Prof Tao Sun and Prof Chen Jiang have made progress in developing a versatile theranostic platform for colorectal cancer peritoneal metastases
2021/07/17
25% of colorectal cancer patients will experience peritoneal metastases (CCPM) due to its natural of serosa infiltration, with a 5-year survival rate less than 10% in clinic. CCPM, which is multiple and scattered, is the terminal stage of colorectal cancer, and the therapy is extremely difficult. CCPM ...
Read More
Dr. Cong Li’ s group revealed an intercellular pathway maintaining the immunosuppressive microenvironment of glioma
2021/06/18
Glioblastoma (GBM) is the most common primary malignant glioma. As a molecular marker, isocitrate dehydrogenase 1 (IDH1) plays a key role in predicting the prognosis of GBM. The vast majority (>90%) of GBM patients belong to the IDH1 wild type (IDH1WT) group, and their median survival (about 13 mon...
Read More
Yong Chu's group has made progress in the study of GSK-3β inhibitor for the treatment of acute promyelocytic leukemia
2021/06/17
Glycogen synthase kinase 3β (GSK-3β) is a highly conserved serine/threonine kinase and named for its ability to phosphorylate and inactivate glycogen synthase. GSK-3β is critical in the regulation of transcription factors and signaling pathways that modulate gene transcription, cell growth, diffe...
Read More
Recent progress of Jun Chen’s group in the development of anti-tumor metastasis therapy
2021/06/10
Metastasis is the foremost cause of cancer-related death. Current clinical treatments, including tumor resection, chemotherapy and radiation therapy, can effectively remove the primary tumor but still fail to inhibit and might even induce tumor metastasis.Therefore, exploring an effective metastasis...
Read More
Recent progress of Chen Jiang’s group in the development of multi-target therapy for the brain microenvironment modulation in the early stage of AD
2021/05/20
Recently, Professor Chen Jiang from School of Pharmacy, Fudan University, has developed a biomimetic dendrimer-peptide nanoconjugate, which had the function of regulating the pro-inflammatory microenvironment of brain lesions and was used for early multi-target treatment of Alzheimer’s disease (AD)...
Read More
Special issue of "New Trends in Virtual Screening", edited by Prof. Renxiao Wang, is just published on-line
2020/10/12
The "New Trends in Virtual Screening" special issue edited by Professor Renxiao Wang from the Department of Medicinal Chemistry, School of Pharmacy, is just published in the Journal of Chemical Information and Modeling (American Chemical Society) as the September issue (https://pubs.acs .org/toc/jci...
Read More
Xiaoyan Shen group disclosed that Sorting Nexin 10 (SNX10) plays an essential role in atherosclerosis
2020/08/03
Cardiovascular disease (CVD) is a leading cause of death and loss of productive life years worldwide1. Atherosclerosis (AS) is the underlying pathological cause for the development of CVDs and the main contributor to cardiovascular mortality2. The predominant cells present in atherosclerotic plaques...
Read More
Advance in Target-drug-delivery for Cerebral Ischemia
2019/12/28
A novel liposome-leukocytes combination delivery system was designed for ischemic stroke target therapy. The study was published on “Science Advances”, with Prof. Jianxin Wang and associate Prof. Jing Qin as co-responding authors.
Read More
A novel PGAM1 allosteric inhibitor discovered by Lu Zhou's lab
2019/10/11
Recently, Lu Zhou's lab from School of Pharmacy, Fudan University, has published a paper entitled "A novel allosteric inhibitor of phosphoglycerate mutase 1 suppresses growth and metastasis of non-small cell lung cancer" in Cell Metabolism (impact factor 22.415), collaborated with Ying Shen's group ...
Read More
Recent progress of Wei Lu’s research group in the development of theranostic formulation for cancer photodynamic immunotherapy
2019/08/29
Recently, Professor Wei Lu from School of Pharmacy, Fudan University, has designed a new theranostic preparation using “hitchhiking technique” for the intraoperative fluorescence image-guided cancer photodynamic and checkpoint blockade therapy. The work has been published entitled “High affinity ...
Read More
Advance in Noninvasive Intraocular Gene Delivery -Flexible octopus-like vectors enabled noninvasive intraocular gene delivery
2019/08/29
Vision has profound influence on the quality of life. Up to now, the number of visually impaired patients worldwide is about 1.3 billion, of which 36 million are blind. Chronic posterior ocular diseases are the causal factors for severe vision impairment and even blindness, including hereditary reti...
Read More
Recent progress of Wei Lu’s research group in the field of development of adjuvant formulation for cancer immunotherapy
2019/07/05
Recently, Professor Wei Lu from School of Pharmacy, Fudan University, has used biomimetic technology to prepare an adjuvant for cancer vaccine. The work has been published entitled “Bacterium-Mimicking Vector with Enhanced Adjuvanticity for Cancer Immunotherapy and Minimized Toxicity” in Advanced ...
Read More
Novel approach in treating acute ischemic stroke
2019/07/05
With the support of National Science Fund for Distinguished Young Scholars and National Natural Science Foundation of China, Prof. Chen Jiang’s group from Fudan University, jointed with Prof. Weigen Lu in China State Institute of Pharmaceutical Industry, led PhD student Yifei Lu and others who deve...
Read More
The team of Professor Xiaoyan Shen from the School of Pharmacy, Fudan University made new progress in the field of autophagy and colorectal cancer
2019/07/01
Recently, the team of Professor Xiaoyan Shen (School of Pharmacy, Fudan University) in collaboration with the team of Zheng Mingyue, a researcher at the Chinese Academy of Sciences Shanghai Institute of Materia Medica, has made new progress in the field of autophagy and colorectal cancer. On June 17...
Read More
Recent progress of professor Di Zhu’s group in the field of colorectal cancer immunotherapy
2019/06/30
Recently, Di Zhu, professor at the School of Pharmacy, and Yuxiong Feng, professor at Zhejiang University, have made new progress in the field of colorectal cancer immunotherapy. This research finding was published online in Science Advances, with the title of "Pharmacological inhibition of β-caten...
Read More
Professor Jun Chen’s group made novel progress in sequentially modulating tumor microenvironment and interfering with cancer cell target
2019/06/03
The limited chemotherapy effect of pancreatic cancer is related to its unique and complex tumor microenvironment (TME). The presence of dense extracellular matrix leads to the low permeability of traditional chemotherapy drugs, and the high toxicity of chemotherapy drugs restricts their clinical app...
Read More
Professor Jun Chen’s group made novel progress in pre-metastatic niche modulation and tumor metastasis suppression
2019/06/03
Metastasis is the major cause of high mortality in cancer patients, thus metastasis suppression is the key and most challenging mission in cancer therapies. Many patients have generated micro-metastasis at the early stage, whereas conventional therapeutic methods or drugs are far less effective agai...
Read More
firstpage
<<previouspage
nextpage>>
endpage
PageNumber
4
/
5
© 2021 School of pharmacy, Fudan University, all rights reserved
杏悦推荐信誉平台
🔊祝大哥2025新的一年里蛇转乾坤，旗开得胜，一路长红，财运缠身，前程似锦，一路辉煌💸💸
杏悦平台注册
绑卡有礼，首存豪礼
杏悦2娱乐开户
注册绑卡送好礼，信誉平台
意昂4体育-凯捷招商
🔥新平台开业，招商代理，待遇丰厚
意昂3体育注册
高赔率，首存豪礼，体育包赔
意昂2体育开户
注册绑卡有礼，超高反水，信誉保障
意昂体育平台
多种体育赛事，最权威体育游戏平台
🔊🔊🔊
杏悦
提供
体育赛事
、
真人娱乐
、
电子游艺
、
电子竞技
、
棋牌游戏
、
彩票投注
等各类游戏娱乐
杏悦
打造顶级的网上娱乐平台，界面美观，速度快，服务优质，安全稳定，带给您最佳游戏体验。
杏悦
全网最佳信誉平台真诚欢迎您！！！
更多杏彩信誉担保平台
杏悦专业提供🪿：
杏悦
🏃🏻♂️➡️、
、
等服务，提供最新官网平台、地址、注册、登陆、登录、入口、全站、网站、网页、网址、娱乐、手机版、app、下载、欧洲杯、欧冠、nba、世界杯、英超等，界面美观优质完美，安全稳定，服务一流，杏悦欢迎您。
杏悦官网xml地图
杏悦 杏悦 杏悦 杏悦 杏悦 杏悦 杏悦 杏悦 杏悦 杏悦
